Abstract:Mediators produced by innate immune response cells such as macrophages can profoundly influence adaptive immunity. Recent studies have shown that interleukin (IL) 18 has an influential role in inflammatory response. Recent data are presented illustrating the importance of IL18 in the induction and perpetuation of chronic inflammation during experimental and clinical rheumatoid synovitis. These findings suggest that antagonists to IL18 may have a role in the treatment of organ specific autoimmune diseases. There is currently considerable interest in the interactive role of innate and adaptive immunity. A large number of mediators have been implicated, particularly those derived from the innate response that can drive the adaptive immunity. In this short review, we will summarise the work carried out in our laboratory on the roles of interleukin (IL) 18 in adaptive immune response and in perpetuating chronic organ specific inflammatory reactions. We will focus primarily on rheumatoid arthritis (RA). The processes that initiate and perpetuate RA are currently unclear. Successful clinical targeting of tumour necrosis factor (TNF) α therefore represents an exciting and important advance, not only in therapeutics but also in understanding the disease pathogenesis. However, non-responder or partial responder patients are not uncommon, and inflammatory disease usually flares on discontinuation of treatment.1,2 This carries significant pathogenetic implications for existing disease models. Moreover, it exemplifies the clinical necessity for generation of further novel, pathogenesis led interventions. One approach to the detection of novel synovial inflammatory pathways is to establish events that regulate synovial TNFα production. Recently, our group has explored the expression of novel cytokine activities in RA synovial membrane that could perpetuate inflammatory synovitis, in particular through modulation of T lymphocyte function and TNFα expression by IL18, an innate cytokine produced principally by macrophages after activation by a range of stimuli, including infection and stress. IL18 is …

Interleukin 18 (IL-18) as a target for immune intervention.

Interleukin-18 and IL-18 Binding Protein

Interleukin-18 in Health and Disease

Interleukin-18: a regulator of cancer and autoimmune diseases

Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment

Role of IL-18 in Transplant Biology

Interleukin-18: recent advances

Interleukin 18: a Pleiotropic Participant in Chronic Inflammation

The Protective Role of Interleukin-18 Binding Protein in a Murine Model of Cardiac Ischemia/reperfusion Injury.

IL-18/IL-18BP and IL-22/IL-22BP: Two interrelated couples with therapeutic potential

Unique Action of Interleukin-18 on T Cells and Other Immune Cells

Interleukin-18 and the pathogenesis of inflammatory diseases

A Unique Dyad in Health and Disease

Interleukin-18 and IL-18BP in inflammatory dermatological diseases

Interleukin-18 Binding Protein (IL-18BP): A Long Journey From Discovery to Clinical Application

The structure and binding mode of interleukin-18

Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-g production from activated B cells (helminthycytokine)

Interleukin-18 treatment options for inflammatory diseases

Role of interleukin 18 in rheumatoid arthritis

Interleukin-19 as an immunoregulatory cytokine.

Homeostatic Defects in Interleukin 18-Deficient Mice Contribute to Protection Against the Lethal Effects of Endotoxin.